This article is more than 5 years old. Information may no longer be current.

OSN’s top news of the week

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are the past week’s top headlines on Healio.com/OSN:

Akorn loses Fresenius appeal; CEO to step down

The Delaware Supreme Court upheld a lower court decision allowing Fresenius Kabi to back out of a $4.3 billion acquisition of Akorn, prompting Akorn CEO Raj Rai to step down. Read more.

FDA approves Alembic’s allergic conjunctivitis treatment

The solution is therapeutically equivalent to Patanol ophthalmic solution 0.1% (Novartis). Read more.

AAO: Keep safety standards high in scope-of-practice expansions

The American Academy of Ophthalmology agrees with a joint federal report’s recommendations on scope of practice. Read more.

Gene therapy fails to show clinical activity in X-linked retinoschisis

The rAAV2tYF-CB-hRS1 intravitreal injection was shown to be safe and well-tolerated in the dose-escalation study, but due to the lack of clinical activity, the company has decided not to move forward with further trials. Read more.

New technology detects firing of nerve cells

The noninvasive technology detects changes in shape in the nerve cells by interferometric imaging that senses alterations in the light passing through the cell or being reflected from its surface. Read more.